Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAB-007
- Development stage
- Preclinical
- Lead developer
- Zhongshan Laibo Ruichen Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RAB-007 is an orally administered small molecule drug candidate under development by ZhongShan LaiBo RuiChen BioMedicine (RabPharma) for the treatment of osteoporosis. Currently in the preclinical stage, the compound is part of a broader pipeline targeting bone and joint health. Specific details regarding its molecular target and mechanism of action have not yet been disclosed by the developer.
Beyond the preview
Go deeper on RAB-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAB-007.